<SEC-DOCUMENT>0001493152-26-011566.txt : 20260319
<SEC-HEADER>0001493152-26-011566.hdr.sgml : 20260319
<ACCEPTANCE-DATETIME>20260319120001
ACCESSION NUMBER:		0001493152-26-011566
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260319
FILED AS OF DATE:		20260319
DATE AS OF CHANGE:		20260319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OKYO Pharma Ltd
		CENTRAL INDEX KEY:			0001849296
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41386
		FILM NUMBER:		26773168

	BUSINESS ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
		BUSINESS PHONE:		44 (0) 207 495 2379

	MAIL ADDRESS:	
		STREET 1:		55 PARK LANE
		CITY:			LONDON
		STATE:			X0
		ZIP:			W1K 1NA
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B> 001-41386</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>OKYO
Pharma LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 19, 2026, OKYO Pharma LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing it has been informed that Panetta Partners
Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 10,119 of the Company&rsquo;s
ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being
furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise
subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company&rsquo;s Registration
Statement on Form F-3 (Reg. No. 333-293145)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
    Pharma LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 19, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Keeren Shah</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
    Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">News Announcement, dated March 19, 2026</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<BR></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OKYO
Pharma Announces Chairman and Founder Acquires Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">London
and New York, NY, March 19, 2026. OKYO Pharma Limited (NASDAQ: <U>OKYO</U>), a clinical-stage biopharmaceutical company developing investigational
therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced it has been informed
that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, has acquired 10,119
of the Company&rsquo;s ordinary shares on NASDAQ at $1.59, bringing his total holding to 10,526,416 shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Urcosimod (formerly called OK-101)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Urcosimod
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been
shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain
mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked
Phase 2a trial involving 18 neuropathic corneal pain subjects. Urcosimod has shown significant pain reduction in an earlier 240 subject
Phase 2, multi-center, double-masked, placebo-controlled trial in DED, which supports the development rationale in NCP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
OKYO Pharma </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">OKYO
Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic
corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused
on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed
a successful phase 2 trial of its flagship drug urcosimod in subjects with NCP and plans to initiate a ~150 subject Phase 2b/3 multiple-dose
study of urcosimod to treat NCP in the first half of this year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
further information, please visit <U>www.okyopharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Inquiries:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Business
    Development &amp; Investor Relations</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    Spencer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+44
    (0)20 7495 2379</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !% 2P# 2(  A$! Q$!_\0
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M-P058_M3?'3&5PRYSXX9.20/WH"#!W,",'_7*_X9B_9M/_-OOP2_\-7X&_\
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MOI'A>3Q?X'U;3!%XATS0+2**QTFYU72=:BM]36Q2*WNKBRBNC D\DKO\>_\
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M^+-Q9JT+>+_'OB'PUJMAK'AO1;R57ET'P#8ZD@MK!;6Z\532ZS(^F:7\0_\
M!5+_ (*X?M"?\%1?BBNI>,VN_AW\ /!^J7,OP@_9\TG4I+S2M AG9+>V\2>.
M+NT6.'QU\3-2B55N-4F@DT[0?/?2O"=A;0W5W<:A^SW_  1>_P"#;W6/C7!X
M._:K_P""@_A[5O#'P@N##X@^'/[,&I0W.E>+_B?9I)(UAXB^+REX+WPEX$O2
MB7FE>"H6B\0^+;*:.\UJ;1='EAM=<Z,GX6R+@/+EQ%QE*CB,SG3?U+*W&E4>
M&G*"J4J6$H3IUJ>-S&,;4\3.O1GA,)1JRG*%2-JE3/,L]S3BO%RR7AOVM+!0
ME%8G,;RBZE*#<93E5TC0H.[<$FW6M'W6VD><?\$=_P!B[_@K9_P4>\2:'\7/
MBS^W1^WI\&_V*M-N_/U'Q_)^U3\;K#QG\9WL.)/"WP<TVZ\<27":8\Z):^(_
MB3JEE%H>G0/=6?A==>URWN4TK]X/^"MG_!*7]K;Q?\--.^*O_!-/]KS]L#X>
M_%GX<^&K;3?$/[/R?M>_'.+PQ\;]"T:RBBBU'P_JFN?$-8M"^,*QP237%WJ%
M_%HOCMW\K56T[58X+ZZ_I)T'0-#\.:+I&@^']&TS0-#T33;/2]&T/1K&VTO1
M]&TRRMX[>STS2],L8XK+3["S@CC@M;.UBCM[>&-(XD5% K2>WA(+&/+!3@@D
M'C)'(YR.=IY(W,!P2#^>YCQQF.,SNEF^%PF6X+#86<OJN50P&!G@Y4).2E3Q
M:C@J?UB=:')*=5*"HU&W@:>%Y*<S[+!<-87#Y8\!6KXRO6JP?M<<\5B/K%.I
M*$5[3"MU[4%%WCRV4IP7+4G9QA3_ ,BGP-_P4[_X*>_LV?&73_$DO[7O[6"_
M$/X4>*;FRU[X;_'+XK_%?QOX9_M;2YC:ZUX,^)/PO\?^)+[3+Z' -IJFEWMG
M;ZI8&5+BRN;"\C@ND_T0/^"37_!97]GW_@I]X%72["6P^%W[4GA#1H;WXI_
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M?VIK,EM> Z1IWY>V.2VE+QM-UH"],G(U:P0,I[?-@CIP<G!XK_7!_P""E_\
MP2]_9S_X*:_""Z\ _&'28_#GQ$T"WN3\(?CMX<T^UD^(7PNUJY?S4^RSR"+^
MWO"%]<83Q+X*U6=M(U6SDEN+9],UF"PUBQ]CB_BC \+YWPYB<?@8XBCB*6:X
M>>,A34\7EJE5P?+B<+!IJISZ0Q:CRUI8:*]E63IJ,O/X<R+$Y[D^=X?"XN5"
MM2Q.%J*BYVPV*LL9:C5MRN,^9WM*3IVY.:,KV7\2?_!M/X=_X)LZ]^U9?_\
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MBH_,_P!B3_OG_P"O2&7&/W<I)./N'CW)&1BOQ923VYO_  &7_P B?IEUW/\
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MDYN>&A65J<N:[IJ:JP;49NI)*4KQ;<4TE9_P$?\ #P[]M88S^V]^TN!C /\
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M34KRLERR2@[_ *"AU/1A_G_/2D=E&W+ ?.HZCJQV@?4L0!ZD@5^ (_X.:?\
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M0VVDV,[[[B$SM&LGF5_GU^,?^"QG_!4#QU#>6>J?MB_$31;.]CECEA\#Z'X
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M>V^G2$7%O9B]CMKB'Z&_X. 9$3_@D!^VI+)(D:_\(5X1+/(RHJY^)/@OJ6P
M.?E!P >.W/S^+SO+\VXGX#H8'%XS,8Y17R? 8C-,?3G1K9A6_M7#UY5N2O5K
M55"G%\G-5JMM):+WF>KA<MQ6"R?B:IB:.'PLLPAC\52P>&J2K4\-!X65/D34
M8P3E*S4:5-*\GNK'\\__  1!_P""Y/[ W[!/[!7A7]GC]H7Q)\3=-^)FF_$G
MXD>*KVS\+?#35_%.D)I7BK5H+W2)$UBUNX[>:6:VAWS0A0\#DQ$':';]>D_X
M.E_^"3"L"WC+XXA?,&6;X)Z^5CWD9/R7C.5 !R$#8&1@\ _(G_!NM_P3_P#V
M%/VD_P#@F?X/^)GQW_9+_9V^-/C^Y^+WQ>T:X\=_$/X6^$/&7B>YTS2=>M8-
M+T^XU[5]-O+^2ST^"3R+.V^T>1;1%1'$I+LW[I)_P2!_X)8"16_X=Y?L>L1(
M& D^ ?P\D!VD ;DDT-T?'.5=2N!RN.L<18C@..?YRL=E?$E;&1S#$K%5L)FN
M74\-4Q+IT5*>&@\-4]E0;Y7:,IRFG+WHMR;O):/$CRK+9X?&953H2P>']C3K
M8#$2J1IN=5PA.?MX-3BG)37*K=FK)?R>?\&P7BC2/''_  5-_;L\;>'VN)?#
MWC7P)\1_&.@37D#VEW/HGBKXY1Z]I,MW9R,TEI=26&H6[W-L[,]O,7A=F*Y/
M][$@58VR54!FRSD*JJ$.YBW1%5%)<]-@8'@FOX+_ /@V8T[1-!_X*S?\%!?#
M_ANTTS2M%T#PM\6-$T70=(CAMM/T/1=&_: DTW2M)TZQB;99Z;I=E;PZ=96J
M*$MH+>.W3 C 'Z^_\'(7_!4E?V+_ -F"Y_9E^#7C(:?^U1^U+HM[X=TV?0;^
M)?%'PN^#UY,NF^-?'5K;VQ.HV/B7Q99/>^!/AW=6XMKRTUG4M0\4Z9<BZ\*)
M',^-<KJYYQSA<LR^$;XO+,CC3D[3AA\,\NC-U,3.,IQ?U?#P<L3-2CS5+<J@
MZL8PCAC%4\LX7K8S&25J.+S!R485$ZE98MM4X0<)U/WLY14=)7BY-RLKK\:_
M^"AWQ8\?_P#!?7_@K/\ "K_@GY\ =<NT_96_9O\ $/B6Y\0^)M*E>31M1'AZ
M^TG2/C?\?-5$3);WL6@V\UE\*?A.UV'CM-3\27]QI\T-UXTGMF\Y_:7^'?C3
M_@VI_P""K_@3X_\ P/T/Q+K?["_QLT^#RO"/]JWVLZAJ7PXDCL+3XP?!G4=7
MUEY3JGCSP!K%NOQ%^%=]J%P]Q?Z3J6BZ'=ZC/-;>([Z?V']A3_@W7_X*=^!_
MA!X7^+WP@_;XU7]A[QA\</!/A+7/'WPZ\%S?$GPKXVL--M1JFI>%/#?CW5_#
M&IZ9)?ZCHMMX@OKV73)E7^RM1U:]MKI'NHF9/H;XR?\ !N9_P52_:#\)CP7\
M=?\ @KKK/QS\+6M^GB#2?"'Q=U7XP^-/#$'B:PL[J#2=32RUG6=4CTZZB6ZF
MMCJ5K:R7-M:W-S)]GNF9HI?K8YEPW@\30R:CQ/DRX3PN7ULHQ^3RH9H\1C:^
M*CRXW-)XFA@Y866-HXFG"KA:R3LHU'!QC*"7C?5,VQ&&JYE4R7,)9]6Q%+'X
M7%^TPL*6$I4:JEA<'3I2Q$9+#SP\ITZT9Q<I.HI25]%_8S\/OB%X(^*_@7P;
M\2?AUXBTWQ?X!^('AG1?&?@KQ7HTK2Z7XB\,:_I]MJFC:M9,Z12B&\L;F";R
MYHHKB$L8;F&"='B7^3'_ (/%2R_LB?LA-%]]?VIM?>+&0PD7X$?$CRS'C#%P
MV-N#GD]<"O%/^#:#_@H-XR^"OQ,\>?\ !'S]KF+4?AU\1_!?B;QFGP(\,>-+
MR,:QX9\=>&Y+Z_\ BO\ L_&?S[BRF94L]6\>^ )=/NY=$US28/$-UX?N[RUO
M-(-Y[+_P>)W,=O\ LA?L?3/+'$T?[5'B"1&D=5PT?P(^)#!P#@85B@;ME@"?
MFKXW(,FJY!XCY/ETJCQ%!XU5\OQ5&I":Q>78S"8N>"Q-.K&48*:IU(7C)T9>
MTA)<D$XQA]'F&/CF?"N/Q,:<J=;ZI6H8G"N+4J.,I-4L12:O[T'-)WA*JG"7
MNNHU>?TE^QO^R?\ \$$O$'[(7[*VN_%GP!_P3ZNOBEK7[-_P0U3XCW7BWQ5\
M.K?Q7=>.]0^&OAJY\6W/B>&[\1PW<7B"YUV2]GUJ.ZABNDU)[LSQ([%5\L_X
M*4_LS?\ !OOX*_82_:B\0?#_ ,-_L6>%_BC8?![QI-\(]5^"_B[PG)\3D^+%
MOI,ES\.+?PE;^&?$%SJ=Y>WGBZ+1K:[L)()=-O=,EOK365;1Y+\U^9/Q3_X-
MB[KXY?L;_LU_M4?L'>*[=?B5\3/V8_@;\2?'/P ^(^LVJ:#XI\9>*?A?X8US
MQ-JWPW^(NJ/Y?AV^\1:Y?:AJ?_"-^+[I_#5O?74J6&MZ)IA@MK7X9_8KT+_@
MCKX#^)&G?LY?\%=/V+OCM^R3\<?!T]CI/B?Q[XG^(OQET/P%J^JEXOLUW\2_
MA^)[/Q)X"T?7;=TG7Q3X2G\0_#S5+*YAUBSU2PT"X&IQ_4X3!X2O7K9IEO&7
M&&9O 9E4Q&-R3 QB\QPT:&/KU:T)8*IG=&I4PR]C.FZ^%HXJ$:4DY4Y-2BO
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M7J$\EY<:UHOB#PY=:EIWB*;6;J:>_P!0U]M3U&^U>\FGO;^^N;B621OY+?\
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IHRE&-6,92BM$W%M=&B)TJ4IJ4J=.4E&24Y4X2G;G>G/*+G;RYK>1_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
